1789 — ScinoPharm Taiwan Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for ScinoPharm Taiwan, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,893	3,083	2,762	3,264	3,186
Cost of Revenue
Gross Profit	1,176	1,317	1,280	1,251	1,216
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	2,627	2,703	2,472	2,858	2,872
Operating Profit	266	380	290	406	314
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	265	359	302	438	349
Provision for Income Taxes
Net Income After Taxes	217	282	243	353	287
Net Income Before Extraordinary Items
Net Income	217	282	243	353	287
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	217	282	243	353	287
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.274	0.355	0.306	0.446	0.363
Dividends per Share